Zhejiang Starry Pharmaceutical Co.,Ltd.

603520

CNE1000026N8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
12.94 ^CNY	+0.54%		+2.94%	-8.10%

Apr. 29	Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zhejiang Starry Pharmaceutical Co.,Ltd.(SHSE:603520) dropped from Shanghai Stock Exchange Health Care Sector Index

December 10, 2021 at 12:00 am EST

Zhejiang Starry Pharmaceutical Co.,Ltd. has been removed from Shanghai Stock Exchange Health Care Sector Index.

Latest news about Zhejiang Starry Pharmaceutical Co.,Ltd.

Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million.	23-08-21	CI
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.	23-07-06	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	23-04-15	CI
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval	23-02-22	MT
Zhejiang Starry Pharma’s CFO Resigns	22-12-19	MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.	22-09-15	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding	22-08-25	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-24	CI
Zhejiang Zhumei Import and Export Group Co., Ltd agreed to acquire Zhejiang Xianju Thermal Power Co., Ltd from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 35 million.	22-03-29	CI
Zhejiang Starry Pharmaceutical Co.,Ltd.(SHSE:603520) dropped from Shanghai Stock Exchange Health Care Sector Index	21-12-10	CI
Zhejiang Hisyn Pharmaceutical Co., Ltd. announced that it has received CNY 110.2637 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	21-11-29	CI
Shanghai Yujun Biological Technology Development Co., Ltd. announced that it expects to receive CNY 38 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	21-11-25	CI
Lansen Pharma Offloads Nearly $4 Million Shares in Zhejiang Starry Pharmaceutical	21-11-05	MT
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Zhejiang Hisyn Pharmaceutical Co., Ltd. announced that it expects to receive CNY 110.2637 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.	21-10-13	CI
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI

Chart Zhejiang Starry Pharmaceutical Co.,Ltd.

Duration

Period

Chart Zhejiang Starry Pharmaceutical Co.,Ltd.

More charts

Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.

Sector

Pharmaceuticals

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Starry Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.94 CNY

Average target price

17.54 CNY

Spread / Average Target

+35.55%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.	-8.10%	613M
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ABBVIE INC.	+3.54%	283B
ASTRAZENECA PLC	+15.83%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B

Other Pharmaceuticals